The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression

Blood

Volumn 98, Issue 3, 2001, Pages 842-850

  Gao, Jin ^a   Richardson, Des R ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DEFEROXAMINE; GENE PRODUCT; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HYDROXYUREA; MESSENGER RNA; PROTEIN P21; PYRIDOXAL ISONICOTINOYLHYDRAZONE; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHELATION; CONTROLLED STUDY; DRUG MECHANISM; GADD45 GENE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; INCUBATION TIME; IRON CHELATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RETINOBLASTOMA; TRANSCRIPTION REGULATION; WAF1 GENE;

EID: 0035437183     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.842     Document Type: Article

References (68)

1. Hoffbrand AV, Ganeshaguru K, Hooton JWL, Tatersall MHN. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol. 1976;33:517-526.
2. Bergeron RJ, Cavanaugh PF Jr, Kline SJ, Hughes RG Jr, Elliot GT, Porter CW. Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. Biochem Biophys Res Commun. 1984;121:848-854.
3. Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-1 iron chelators in leukemic cell lines. Cancer Res. 1992;52:4591-4599.
4. Seligman PA, Schleicher RB, Siriwardana G, Domenico J, Gelfand EW. Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation. Blood. 1993;82:1608-1617.
5. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, Planap RP. Tumor cell cytotoxicity of a novel metal chelator. Blood. 1998;92:1384-1389.
6. Donfrancesco A, Deb G, De Sio L, Cozza R, Castellano A. Role of desferrioxamine in tumor therapy. Acta Haematol. 1996;95:66-69.
7. Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol. 1997;75:1164-1180.
8. Estrov Z, Tawa A, Wang X-H, et al. In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood. 1987;69:757-761.
9. Dezza L, Cazzola M, Danova M, et al. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia. 1989;3:104-107.
10. Hann H-WL, Stahlhut MW, Rubin R, Maddrey WC. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 1992;70:2051-2056.
11. Blatt J, Stitely S. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. 1987;47:1749-1750.
12. Becton DL, Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988;48:7189-7192.
13. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990;50:4929-4930.
14. Donfrancesco A, Deb G, Dominici C, et al. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol. 1992;15:319-322.
15. Donfrancesco A, De Bernardi B, Carli M, et al. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur J Cancer. 1995;31A:612-615.
16. Richardson DR. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leuk Lymphoma. 1998;31:47-60.
17. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998;131:306-315.
18. Richardson DR, Tran E, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995;86:4295-4306.
19. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood. 1997;89:3025-3038.
20. Darnell G, Richardson DR. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, III: the effect of the ligands on molecular targets involved in proliferation. Blood. 1999;94:781-792.
21. Richardson DR, Bernhardt P. Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with pronounced antitumor activity. J Biol Inorg Chem. 1999;4:266-273.
22. Thelander L, Reichard P. The reduction of ribonucleotides. Annu Rev Biochem. 1979;48:133-158.
23. Thelander L, Gräslund A, Thelander M. Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun. 1983;110:859-865.
24. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Gräslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 1993;268:26200-26205.
25. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack, Porter R. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem. 1996;271:20291-20299.
26. Lederman HM, Cohen A, Lee JWW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S phase inhibitor of human lymphocyte proliferation. Blood. 1984;64:748-753.
27. 1 phase of the cell cycle. Cancer Res. 1993;53:3968-3975.
28. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potent mediator of p53 suppression. Cell. 1993;75:817-825.
29. Harper JW, Adam GR, Wei N, Keyomars K, Elledge SJ. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
30. Levine AJ. p53, The cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
31. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391-3395.
32. Zeng Y-X, El-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 1996;12:1557-1564.
33. OtaniFujita N, Minami S, Mimaki S, Dao S, Sakai T. p53-Independent activation of the gadd45 promoter by delta (12)-prostaglandin J (2). Biochem Biophys Res Commun. 1998;251:648-652.
34. Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7-23.
35. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551-555.
36. Zetterberg A, Larsson O, Wiman KG. What is the restriction point? Curr Opin Cell Biol. 1995;7:835-842.
37. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365:349-352.
38. Donnellan R, Runjan C. Cyclin E in human cancers. FASEB J. 1999;13:773-780.
39. Heichman KA, Roberts JM. Rules to replicate by. Cell. 1994;79:557-562.
40. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem. 1998;273:1-4.
41. Johnson DK, Murphy TB, Rose NJ, Goodwin WH, Pickart L. Cytotoxic chelators and chelates, I: inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(Il) complex of salicylaldehyde benzoyl hydrazone. Inorg Chim Acta. 1982;67:159-165.
42. Richardson DR. Cytotoxic analogues of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effect of complexation with copper(II), gallium(III), and iron(III) on their antiproliferative activity. Antimicrob Agents Chemother. 1997;41:2061-2063.
43. Richardson DR, Baker E. The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta. 1990;1053:1-12.
44. Richardson DR, Baker E. Two mechanisms of iron uptake from transferrin by melanoma cells: the effect of desferrioxamine and ferric ammonium citrate. J Biol Chem. 1992;267:13972-13979.
45. Ponka P, Grady RW, WilczynskaA, Schulman HM. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim Biophys Acta. 1984;802:477-489.
46. Davidoff AM, Pence JC, Shorter NA, Ingelhart JD, Marks JR. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene. 1992;7:127-133.
47. Moll UM,OstermeyerAG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol. 1996;16:1126-1137.
48. Ronca F, Chan S-L, Yu VC. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY-5Y, through a p53-dependent pathway. J Biol Chem. 1997;272:4252-4260.
49. Sewing A, Ronicke V, Burger C, Funk M, Muller R. Alternative splicing of human cyclin E. J Cell Sci. 1994;107:581-588.
50. Mumberg D, Wick M, Burger C, Hass K, Funk M, Muller R. Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation. Nucleic Acids Res. 1997;25:2098-2105.
51. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent Go/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage, Genes Dev. 1996;10:934-947.
52. Nyholm S, Thetander L, Gräslund A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry. 1993;32:11569-11574.
53. Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JA. p53 In chronic myeloid leukemia cell lines. Leukemia. 1992;6:839-842.
54. Vojtesek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Life Sci. 1993;105:607-612.
55. Lohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol. 2000;10:197-202.
56. Kulp KS, Green SL, Vulliet R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp Cell Res. 1996;229:60-68.
57. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol. 1995;15:4215-4224.
58. Simonart T, Degraef C, Andrei G, et al. Iron chelators inhibit the growth and induce apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol. 2000;115:893-900.
59. Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy: the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues. J Lab Clin Med. 1999;134:510-521.
60. Lucas JJ, Terada N, Szepsi A, Gelfand EW. Regulation of synthesis of p34cdc2 and its homologues and their relationship to p110Rb phosphorylation during cell cycle progression of normal human T cells. J Immunol. 1992;148:1804-1811.
61. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol. 2000;20:3224-3233.
62. Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15:3463-3469.
63. Kung AL, Sherwood SW, Schmike RT. Differences in the regulation of protein synthesis, cyclin B accumulation, and cellular growth in response to the inhibition of DNA synthesis in Chinese hamster ovary and HeLa S3 cells. J Biol Chem. 1993;268:23072-23080.
64. Ikegami S, Taguchi T, Ohashi M, Oguro M, Nagano H, Mano Y. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. Nature. 1978;275:458-460.
65. Kung AL, Sherwood SL, Schimke RT. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci U S A. 1990;87:9553-9557.
66. Schimke RT, Kung AL, Rush DF, Sherwood SW. Differences in mitotic control among mammalian cells. Cold Spring Harbor Symp Quant Biol. 1991;56:417-423.
67. Renton FJ, Jeitner TM. Cell cycle-dependent inhibition of the inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem Pharmacol. 1996;51:1553-1561.
68. Caraglia M, Tagliaferri P, Budillon A, Abbruzzese A. Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. Adv Exp Med Biol. 1999;472:187-198